Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.81 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.69 |
| ▸ | ADRA1D | P25100 | 6/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.60 |
| ▸ | ADRA1B | P35368 | 6/20 | 0.60 |
| ▸ | HTR1A | P08908 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | THPO | P40225 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butamoxane SCHEMBL29354372 | 1.00 | POLB (0.81) | POLBESR2SMN1; SMN2ALDH1A1ADRA1D | |
| SCHEMBL29353196 | 0.91 | POLB (0.97) | POLBESR2SMN1; SMN2ALDH1A1ADRA1D | |
| SCHEMBL10864903 | 0.91 | POLB (0.97) | POLBESR2SMN1; SMN2ALDH1A1ADRA1D | |
| SCHEMBL7460800 | 0.85 | SMN1; SMN2 (0.71) | POLBESR2SMN1; SMN2ALDH1A1ADRA1D | |
| SCHEMBL7277047 | 0.85 | SMN1; SMN2 (0.71) | POLBESR2SMN1; SMN2ALDH1A1ADRA1D | |
| SCHEMBL8797418 | 0.85 | SMN1; SMN2 (0.71) | POLBESR2SMN1; SMN2ALDH1A1ADRA1D | |
| SCHEMBL7463106 | 0.85 | SMN1; SMN2 (0.71) | POLBESR2SMN1; SMN2ALDH1A1ADRA1D | |
| SCHEMBL7460809 | 0.85 | SMN1; SMN2 (0.71) | POLBESR2SMN1; SMN2ALDH1A1ADRA1D | |
| SCHEMBL9619567 | 0.85 | POLB (0.71) | POLBESR2SMN1; SMN2ALDH1A1ADRA1D | |
| SCHEMBL18358970 | 0.84 | POLB (0.75) | POLBESR2SMN1; SMN2ALDH1A1ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-12102653-B2 | Ligand regulated protein-protein interaction system | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2024-10-01 | — | — | US | disclosed |
| US-20240000841-A1 | LIGAND REGULATED PROTEIN-PROTEIN INTERACTION SYSTEM | ST ANNA KINDERKREBSFORSCHUNG (AT) | 2024-01-04 | — | — | US | disclosed |
| US-11844813-B2 | Ligand regulated protein-protein interaction system | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2023-12-19 | — | — | US | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-20220041687-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2022-02-10 | — | — | US | disclosed |
| US-20210386781-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | UNIVERSITÄT FÜR BODENKULTUR WIEN (AT) | 2021-12-16 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-20050002865-A1 | Diagnostic/therapeutic agents | AMERSHAM HEALTH AS (NO) | 2005-01-06 | — | — | US | disclosed |
| US-20040141922-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2004-07-22 | — | — | US | disclosed |
| US-6680047-B2 | FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2004-01-20 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040141922-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | POLB 989/4885ESR2 1745/4885SMN1; SMN2 1551/4885 |
| US-20050002865-A1 | Diagnostic/therapeutic agents | FUS, HNRNPF, HNRNPR | POLB 648/4885ESR2 1111/4885SMN1; SMN2 1857/4885 |
| US-20220041687-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | CARS1, CD74, HAVCR2 | POLB 4881/4885ESR2 1225/4885SMN1; SMN2 4302/4885 |
| US-20210386781-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | CD74, HAVCR2, CD2BP2 | POLB 4811/4885ESR2 1723/4885SMN1; SMN2 4079/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | POLB 967/4885ESR2 1929/4885SMN1; SMN2 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.